The researchers demonstrated that they could recapitulate sensitivity and innate resistance to PD-1 blockade ex vivo with an assay developed on AIM chips. They were able to profile the functional response to tumor PD-1 blockade ex vivo and unveil a novel strategy to advance precision immuno-oncology. ​

AIM Biotech was lauded as one of only 3 companies (and the only startup) showcasing innovative products at the conference. The following 2 paragraphs are excerpts from the article.

"Technology Networks met with a range of companies from big name instrument vendors to small start-ups, but for three notable exceptions there was not much innovation on display, instead new applications of existing technologies, and developments of existing products."  

"...  start-up AIM Biotech (spun out of MIT) with its 3D cell culture chip for modelling complex biological systems. The all-plastic chip contains interlinked channels filled with gel in which cells can grow. AIM provided a nice application of the system for modelling the metastasis of breast cancer into bone marrow. Here users can create 3D blood vessels, bone cells and stem cells in the gel to mimic the living marrow of a bone, and were able to model the spread of cancer cells into the marrow microenvironment. The various cell types behaved as they normally would in a clinical setting."

Read the full article here  (free registration required)